Appendix 4D & Half-Year Financial Statements
Filed with ASX · · 23 pages · English
Cynata Therapeutics Limited on 6ix
Earlier from Cynata Therapeutics
- December 2025 Quarterly Activity Report and Appendix 4C
- Cynata Completes $1.2m At-The-Market Raise
- Patient Enrolment Complete in Phase 2 aGvHD Clinical Trial
- Patient Enrolment Completed in Phase 2 aGvHD Clinical Trial
- Positive DSMB Review in Phase 1/2 Kidney Transplant Trial
Later from Cynata Therapeutics
- Last Visit in GvHD Trial Completed
- March 2026 Quarterly Activity Report & Appendix 4C
- Cynata Secures Commitments for $1.5m Placement
- EU Positive Opinion on CYP-001 Paediatric Investigation Plan
- Suspension from Quotation
Follow Cynata Therapeutics into a list and get an email when it puts out news.
Follow Cynata Therapeutics